Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 13, Issue 9, 1998, Pages 625-630

  Macgowan, Sian H ^a   Wilcock, Gordon K ^a   Scott, Margaret ^b  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b BLACKBERRY HILL HOSPITAL   (United Kingdom)

Author keywords

Anticholinesterase; Apolipoprotein E genotype; Galanthamine; Gender; Tacrine

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; GALANTAMINE; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENOTYPE; GERONTOPSYCHIATRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; SEX DIFFERENCE; TIME; UNITED KINGDOM;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; GENOTYPE; HUMANS; MALE; SEX CHARACTERISTICS; TACRINE; TIME FACTORS;

EID: 0031657809     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2     Document Type: Article

References (27)

1. Ahlin, A., Junthe, T., Hassan, M. and Nyback, H. (1995) One year on tacrine (THA): Clinical and biochemical effects in patients with dementia of the Alzheimer's type. Int. Psychogeriat. 7(1), 75-83.
2. Allen, S. J., Dawbarn, D., MacGowan, S. H., Wilcock, G. K., Treanor, J. J. S. and Moss, T. H. (1990) A quantitative morphometric analysis of basal forebrain neurones expressing β-NGF receptors in normal and Alzheimer's disease brains. Dementia 1, 125-127.
3. Altstiel, L., Mohs, R., Marin, D. et al. (1995) ApoE genotype and clinical outcome in Alzheimer's disease. In Apolipoprotein E et Maladie D'Alzheimer. Fondation Ipsen, Paris.
4. Amberia, K., Norberg, A., Viitanen, M. and Winblad, B. (1993) Long-term treatment with tacrine (THA) in Alzheimer's disease - evaluation of neuropsychoiogical data. Acta Neurol. Scand., Suppl. 149, 55-57.
5. Bachman, D. L., Wolf, P. A., Lin, R. T., Knoefel, J. E., Cobb, J., Belanger, A., D'Agostino, R. B. and White, L. R. (1992) Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 42, 115-119.
6. Bird, T. D., Stranahan, S. and Raskind, M. (1983) Alzheimer's disease: Choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann. Neurol. 14, 284-293.
7. Eagger, S. A., Richards, M. and Levy, R. (1994) Long-term effects of tacrine in Alzheimer's disease: An open study. Int. J. Geriatr. Psychial. 9, 643-647.
8. Farlow, M. R., Lahiri, D. K., Poirier, J., Davignon, J. and Hui, S. (1997) Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. N. Y. Acad. Sci. 802, 101-110.
9. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975) Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 12, 189-198.
10. Goate, A., Chartier-Harlin, M-C., Mullan, M., Brown, J., Crawford, F. and Fidani, L. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
11. Katzman, R. (1994) Alzheimer's Disease. Raven Press, New York.
12. Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S. and Gracon, S. I. (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271, 985-991.
13. Lucotte, G., Oddoze, C. and Michel, B-F. (1996) Apolipoprotein E genotype allele ε4 and response to tacrine in Alzheimer's disease. Alzheimer Res. 2, 101-102.
14. McKhann, G., Drachman, E., Folstein, M. et al. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
15. Perry, E. K., Tomlinson, B. E., Blessed, G. et al. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Brit. Med. J. 2, 1457-1459.
16. Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Betrand, P., Nalbantoglu, J., Gilfix, B. M. et al. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Nat. Acad. Sci. USA 92, 12260-12264.
17. Richard, F., Helbecque, N., Neuman, E., Guez, D., Levy, R. and Amouyel, P. (1997) ApoE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349, 539.
18. Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Holman, K., Tsuda, T. et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778.
19. Rosen, W. G., Mohs, R. C., and Davis, K. L. (1984) A new rating scale for Alzheimer's disease. Am. J. Psychiat. 141, 1356-1364.
20. Rossor, M. N., Garrett, N. J., Johnson, A. L. et al. (1982) A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 105, 313-330.
21. Sherrington, R., Rogaev, E. I., Laing, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Holman, K. et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
22. Solomon, P. R., Knapp, M. J., Gracon, S. I., Groccia, M. and Pendlebury, W. W. (1996) Long-term tacrine treatment in patients with Alzheimer's disease. Lancet 348, 275-276.
23. Wenham, P. R., Price, W. H. and Blundell, G. (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158-1159.
24. Wilcock, G. K. and Esiri, M. M. (1982) Plaques, tangles and dementia: A quantitative study. J. Neurol. Sci. 56, 343-356.
25. Wilcock, G. K., MacGowan, S. H., Scott, M. and Dawbarn, D. (1995) Apolipoprotein E genotype and response to tacrine in Alzheimer's disease. In Apolipoprotein E et Maladie D'Alzheimer. Fondation Ipsen, Paris.
26. Wilcock, G. K., Scott, M. and Pearsall, T. (1994) Long-term use of tacrine. Lancet 343, 294.
27. Wilcock, G. K., Surmon, D. J., Scott, M., Boyle, M., Mulligan, K. and Neubauer, K. A. (1993) An elevation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing 22, 316-324.